[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundacio Privada Mon Clinic Barcelona\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100582415","eus-guided-portal-pressure-gradient-ppg-measurement-a-potential-alternative-to-the-traditional-hvpg-100582415",false,"NCT06863012","EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG","EUS-PPG","Inclusion Criteria:\n\n* Subjects must be 18 to 85 years of age inclusive, at the time of signing the informed consent form.\n* Subjects who have a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement.\n* Subjects capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Significant bleeding risk (International Normalized Ratio (INR) \\> 1.5 OR platelet count \\\u003C 50000).\n* Presence of active gastrointestinal bleeding at the time of screening\n* History of any blood thinner consumption (e.g. warfarin, heparin, novel roal anticoagulants) within the last 5 days.\n* Presence of massive ascites causing abdominal distension or requiring frequent therapeutic paracentesis.\n* Subjects having received previous Transjugular Intrahepatic Portosystemic Shunt (TIPS) or Surgical Portosystemic Shunt.\n* Hepatocellular carcinoma not meeting Milan Criteria.\n* Presence of portal vein thrombosis or another suspected component of presinusoidal portal hypertension.\n* Presence of extra-hepatic cancer, terminal disease, or severe comorbidities significantly limiting life expectancy or affecting study participation.\n* Stenosis or surgical anatomical alterations of the gastrointestinal tract that could preclude endoscopic access with the echoendoscope.","ALL","18 Years","85 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative to the traditional hepatic venous pressure gradient (HVPG) method in patients with portal hypertension due to chronic liver disease. The main questions it aims to answer are:\n\n* What is the correlation between EUS-PPG and HVPG measurements in patients with portal hypertension due to cirrhosis?\n* Can EUS-PPG serve as a reliable and less invasive alternative to HVPG for assessing portal pressure?\n* What are the safety outcomes associated with EUS-PPG compared to HVPG?\n\nResearchers will compare EUS-PPG measurements with HVPG measurements within the same patients to assess whether EUS-PPG provides accurate and clinically comparable portal pressure readings while reducing procedural risks.\n\nParticipants will:\n\n* Be adults aged 18 to 85 with a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement.\n* Undergo both EUS-PPG and HVPG measurements within a seven-day window to allow for direct comparison of results.\n* Receive standard clinical care for their condition, including routine diagnostic evaluations and portal hypertension management as needed.\n* Be monitored for safety outcomes, including adverse events such as bleeding, infection, perforation, and any other complications related to the procedure.\n* Provide relevant demographic and clinical data, including liver disease history, Child-Pugh and MELD scores, and portal hypertension-related complications such as varices or ascites.",[27,28,29],"Portal Hypertension","Chronic Liver Disease (CLD)","Cirrhosis",[31,32,33,34],"Hepatic Venous Pressure Gradient","Endoscopic Ultrasound-Guided Portal Pressure Gradient","Portal hypertension","Non-Invasive Diagnostic Methods for Portal Hypertension","RECRUITING","2025-08-11",{"date":38,"type":39},"2025-08-12","ACTUAL",{"date":41,"type":39},"2025-04-16",{"date":43,"type":21},"2025-12",{"name":45,"class":46},"Fundacio Privada Mon Clinic Barcelona","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100562787","changes-in-eye-pressure-in-glaucoma-patients-treated-with-istent-inject-w-monitored-by-a-contact-lens-sensor-100562787","NCT06607705","Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens Sensor","Fluctuations of the Intraocular Pressure in Surgically Treated Glaucoma Patients with IStent Inject W by a Contact Lens Sensor","Inclusion Criteria:\n\n* Adult Patients (over 18 years old) with an initial diagnosis of POAG requiring an indication from the patient chart of an untreated IOP of over 21 mm Hg. Diagnosis of NTG requiring an untreated mean diurnal IOP of over 21 mm Hg from diagnosis to enrollment, indicated by the patient chart. Ocular hypertension is defined as a condition in which the IOP was greater than 21 mm Hg in the absence of glaucomatous defects in visual field testing, the normal appearance of the optic disc and nerve fiber layer, anatomic normality, open angles in gonioscopy, and the absence of ocular conditions contributing to the elevation of pressure, such as narrow angles, neovascular conditions, and uveitis.\n* Adult Patients (over 18 years old ) diagnosed with POAG and NTG are defined as those with open normal appearing angles, typical glaucomatous optic atrophy (i.e., neural rim thinning, notching, saucerization, or nerve fiber layer disc haemorrhage), and typical glaucomatous visual field damage (i.e., arcuate, paracentral scotoma, or nasal step).\n* Adult Patients (age over 18 years old ):\n\nwith unilateral or bilateral open-angle glaucoma (POAG) without previous eye surgery, treated with topical anti-glaucoma medications, who need glaucoma surgery with iStent inject W. The investigators will include patients with isolate iStent surgery and patients with combined cataract and iStent surgery. In cases of bilateral glaucoma, the two eyes of the same patient may be included consecutively.\n\nFor the control group only: Patients with topical hypotensive glaucoma treatment requiring cataract surgery.\n\nExclusion Criteria:\n\n* Age under 18 years\n* Visual defects attributable to nonglaucomatous conditions, primary angle closure glaucoma, neovascular glaucoma, history of ocular trauma, retinal disease or ocular inflammation, and laser therapy or secondary glaucoma.\n* The patients have to meet best-corrected Snellen visual acuity of under 0.3 and spherical equivalent of under 6 diopter.\n* We will not include patients with previous ocular surgery, except cataract surgery performed at least 6 months prior to the inclusion date.",{"count":56,"type":21},53,[24],"The purpose of this study is to compare the IOP-related fluctuations using the CLS (contact lens sensor) Sensimed Triggerfish in glaucoma patients before and after glaucoma surgery with iStent inject W under physiological conditions and compare these results with a control group of glaucoma patients treated only with hypotensive medical treatment requiring cataract surgery.",[60],"Glaucoma Eye",[62,63,64,65,66,67,68,69],"intraocular pressure (IOP)","glaucoma","cataract","ophthalmology","Contact Lens Sensor (CLS)","Glaucoma surgery","iStent inject W","Sensimed Triggerfish","2025-03-04",{"date":72,"type":39},"2025-03-06",{"date":74,"type":39},"2024-10-21",{"date":76,"type":21},"2025-10-01",{"name":45,"class":46},2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":47},"100572618","respiratory-syncytial-virus-infection-in-exacerbations-of-chronic-obstructive-pulmonary-diasease-the-recode-study-100572618","NCT06735612","Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study","RECODE","Inclusion Criteria:\n\n* Female or male\n* ≥50 years of age\n* Seeking urgent medical attention because of ECOPD, as defined by the Rome consensus definition: \"in a patient with COPD, an exacerbation is an event characterized by dyspnea and\u002For cough and sputum that worsen over \\\u003C14 d, which may be accompanied by tachypnoea and\u002For tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways\"\n\nExclusion Criteria:\n\n* Previous RSV vaccination (other vaccines will be allowed and recorded)\n* Active cancer (or any other disease) that may alter the immune status of the patient\n* Neurologic disorders that incapacitate the participation of the patient\n* No signing of the informed consent","50 Years",{"count":88,"type":21},892,"OBSERVATIONAL","The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) who experience exacerbations during the RSV season (October-April). The main question it aims to answer is:\n\n* What is the prevalence of RSV infection in patients with COPD during exacerbations in the RSV season?\n* Does RSV infection lead to worse clinical outcomes, including hospitalization, longer length of stay, acute cardiovascular events, and\u002For death in patients with COPD exacerbations?\n\nResearchers will compare patients with RSV infection to those without RSV infection to see if RSV infection results in worse clinical outcomes, such as increased hospitalization, longer stays, cardiovascular events, or death.\n\nParticipants will:\n\n* Be adults diagnosed with COPD who present to the emergency department or day hospital due to acute exacerbations of their respiratory symptoms.\n* Receive treatment as per standard clinical care for COPD exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may complete a course of antibiotics and\u002For oral corticosteroids if prescribed during hospitalization.\n* Undergo diagnostic testing for RSV infection as part of the clinical routine to determine the presence or absence of the virus during their exacerbation.\n* Have clinical outcomes monitored, including hospitalization rate, length of stay, and any acute cardiovascular events, as well as mortality during the exacerbation period.\n* Provide relevant demographic and clinical data, including medical history, COPD severity, comorbidities, and previous exacerbation events.",[92,93,94,95],"Respiratory Synctial Virus","COPD","Chronic Obstructive Pulmonary Disease (COPD)","Exacerbation of COPD","2025-02-25",{"date":98,"type":39},"2025-02-26",{"date":100,"type":39},"2024-12-16",{"date":102,"type":21},"2025-09",{"name":45,"class":46},""]